Clinical trial • Phase III • Gastroenterology
Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate for Acute pancreatitis
Phase III trial of Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate for Acute pancreatitis.
Overview
- Trial Therapeutic Area
- Gastroenterology
- Trial Disease
- Acute pancreatitis
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
Key dates
- Initial CTIS Submission Date
- 08-03-2024
- First CTIS Authorization Date
- 17-05-2024
Trial design
Randomised, open-label, two active comparator arms: ringer's lactate solution (ringer laktát hartmann "baxter" solution for infusion) versus normal saline (nátrium-klorid eurolife 0,9% solution for infusion). dose/schedule not specified in the record.-controlled Phase III trial across 1 site in Hungary.
- Randomised
- Yes
- Open Label
- Yes
- Comparator
- Two active comparator arms: Ringer's lactate solution (Ringer Laktát Hartmann "Baxter" solution for infusion) versus Normal saline (Nátrium-klorid EUROLIFE 0,9% solution for infusion). Dose/schedule not specified in the record.
- Target Sample Size
- 720
- Trial Duration For Participant
- 7
Eligibility
Recruits 720 No vulnerable populations selected; informed consent is required ("Signature of informed consent"). No assent procedures or specific provisions for minors described; trial inclusion starts at 18 years of age..
- Vulnerable Population
- No vulnerable populations selected; informed consent is required ("Signature of informed consent"). No assent procedures or specific provisions for minors described; trial inclusion starts at 18 years of age.
Inclusion criteria
- {"criterion_text":"- 18 years of age"}
- {"criterion_text":"- Diagnosis of acute pancreatitis according to the revision of the Atlanta classification (Banks et al, Gut 2013), which requires at least two of the following three criteria: A) typical abdominal pain, B) increase in serum amylase or lipase levels higher than three times the upper limit of normality, and C) signs of acute pancreatitis in imaging"}
- {"criterion_text":"- Signature of informed consent"}
Exclusion criteria
- {"criterion_text":"- New York Heart Association class II heart failure (slight limitation of physical activity; fatigue, palpitations, or dyspnea with ordinal physical activity) or worse, or ejection fraction <50% in the last echocardiography"}
- {"criterion_text":"- Chronic pancreatitis defined by a Wirsung duct ≥4mm and/or pancreatic calcifications"}
- {"criterion_text":"- More than 1 previous episode of acute pancreatitis (only 2 episodes of acute pancreatitis are allowed, one of them the present episode)"}
- {"criterion_text":"- Decompensated cirrhosis (Child’s class B or C)"}
- {"criterion_text":"- Hyper or hyponatremia (<135 or >145 mEq/L)"}
- {"criterion_text":"- Hyperkalemia (>5 mEq/L)"}
- {"criterion_text":"- Hypercalcemia (albumin or protein-corrected calcium >10.5 mg/dL or 2.62 mmol/L)"}
- {"criterion_text":"- Criteria for moderately severe or severe acute pancreatitis (revision of the Atlanta classification, Banks et al, Gut 2013) at recruitment: any of the following: A) presence of creatinine ≥1.9 mg/dL or ≥170 mmol/l, B) PaO2/FiO2≤300, C) systolic blood pressure <90 mmHg despite initial fluid resuscitation, D) presence of local complications (acute peripancreatic fluid collections, acute necrotic collection, pseudocyst, walled-off necrosis, gastric outlet dysfunction, splenic or portal vein thrombosis, or colonic necrosis), E) exacerbation of previous comorbidity such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis"}
- {"criterion_text":"- Signs of volume overload or heart failure at recruitment (peripheral edema, pulmonary rales, or increased jugular ingurgitation at 45º)"}
- {"criterion_text":"- Time from pain onset to arrival to emergency room >24 h"}
- {"criterion_text":"- Time from confirmation of pancreatitis to randomization >8 h"}
Endpoints
Primary endpoints
- {"endpoint_text":"- The primary outcome will be moderately severe to severe AP, according to the revision of the Atlanta classification. The primary safety outcome will be a composite variable involving any of the following: fluid overload, acute kidney injury, hyperkalemia, hypercalcemia, or acidosis.","definition_or_measurement_approach":"Severity classified using the revision of the Atlanta classification (Banks et al, Gut 2013). Safety measured as a composite of specified events: fluid overload, acute kidney injury, hyperkalemia, hypercalcemia, or acidosis."}
Recruitment
- Planned Sample Size
- 720
- Recruitment Window Months
- 13
- Consent Approach
- Informed consent required: "Signature of informed consent". Participants (adult, ≥18 years) provide written consent. No information on assent or age-specific consent forms or languages provided.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 720
Hungary
- Earliest CTIS Part Ii Submission Date
- 29-04-2024
- Latest Decision Or Authorization Date
- 17-05-2024
- Processing Time Days
- 18
- Number Of Sites
- 1
- Number Of Participants
- 720
Sites
- Site Name
- Semmelweis University
- Department Name
- Department for Pancreatic Disorders
- Principal Investigator Name
- Péter Hegyi
- Principal Investigator Email
- hegyi.peter@semmelweis.hu
- Contact Person Name
- Péter Hegyi
- Contact Person Email
- hegyi.peter@semmelweis.hu
- Number Of Participants
- 720
Sponsor
Primary sponsor
- Full Name
- Semmelweis University
- Organisation Type
- Educational Institution
- Country Of Registered Address
- Hungary
Investigational products
- Investigational Product Name
- Ringer Laktát Hartmann „Baxter” oldatos infúzió
- Active Substance
- Potassium chloride; Sodium chloride; Calcium chloride dihydrate; Sodium lactate
- Modality
- Small molecule
- Routes Of Administration
- Infusion
- Route
- Infusion
- Authorisation Status
- Authorised (marketing authorisation: OGYI-T-9472/03, HU)
- Maximum Dose
- Max daily dose: 4000 ml; Max total dose: 28000 ml
- Investigational Product Name
- Nátrium-klorid EUROLIFE 0,9% oldatos infúzió
- Active Substance
- Sodium chloride
- Modality
- Small molecule
- Routes Of Administration
- Infusion
- Route
- Infusion
- Authorisation Status
- Authorised (marketing authorisation: OGYI-T-24135/01, HU)
- Maximum Dose
- Max daily dose: 4000 ml; Max total dose: 28000 ml
Related trials
Other published trials that may interest you.